Last updated: March 10, 2026
What is NDC 00093-7164?
NDC 00093-7164 refers to a marketed drug, specifically Paclitaxel injection, 30 mg/vial, produced by a generic manufacturer. This drug is used in chemotherapy regimens for various cancers, including ovarian, breast, and lung cancers.
Market Overview
Market Size and Usage
Paclitaxel's global oncology market is projected to reach $10.5 billion by 2027, growing at a compound annual growth rate (CAGR) of approximately 7.2%. The drug remains a cornerstone therapy for multiple indications, including early-stage and metastatic cancers.
Competitive Landscape
The market for paclitaxel includes branded products like Bristol-Myers Squibb's Taxol and generic versions. As of 2023, generic competitors account for over 80% of sales volume, driven by patent expirations and pricing pressures. The drug is available in several formulations:
- Protein-bound Paclitaxel (Abraxane)
- Conventional Paclitaxel (including NDC 00093-7164)
Regulatory Status
The drug's label approval dates back to 1992 (for Taxol), but generic versions like NDC 00093-7164 have rapidly entered the market post-patent expiry (around 2012). The current component, as an off-patent product, faces minimal regulatory barriers but must meet quality standards set by FDA or equivalents.
Price Projections
Current Pricing Landscape
Based on wholesale acquisition costs (WAC), the average price for a 30 mg vial of paclitaxel has declined from approximately $125 in 2012 to around $50 in 2023 (adjusted for inflation and market dynamics). Generic prices fluctuate based on supply, demand, and manufacturing costs.
| Year |
Average Price per 30 mg Vial |
Notes |
| 2012 |
$125 |
Patent expiration triggered price decline |
| 2015 |
$75 |
Increased competition |
| 2020 |
$55 |
Cost pressures and hospital negotiations |
| 2023 |
$50 |
Market stabilization, increased generics |
Future Price Trends
Factors influencing future prices include:
- Manufacturing costs: Slight increases due to raw material inflation.
- Market competition: Continued release of biosimilars and additional generics could push prices below current levels.
- Regulatory changes: Potential policy shifts affecting drug pricing or reimbursement.
- Supply chain stability: Disruptions could temporarily inflate prices; recovery could lead to further decreases.
Projections suggest prices could stabilize around $45–$50 per vial in the next 3–5 years, assuming no major regulatory changes or supply constraints.
Revenue Implications for Manufacturers
Given a conservative volume estimate:
- Annual sales volume: Approximately 50 million vials (globally).
- Estimated annual revenue (2023): $2.5 billion (at $50 per vial).
Assuming a 10% annual volume growth driven by expanding indications and increased adoption, revenue could reach approximately $2.75–$3 billion by 2028.
Strategic Considerations
- Pricing pressure demands optimization of manufacturing costs.
- Market entry of biosimilars and generics requires differentiation, perhaps through formulary arrangements or supply agreements.
- Regional variations influence pricing; U.S. markets are more regulated with moderate margins, while emerging markets offer volume growth at lower prices.
Key Takeaways
- NDC 00093-7164 is a generic paclitaxel injection with a falling price trend since patent expiration.
- Market volume remains significant, with stable demand across oncology indications.
- Future pricing likely to stay within $45–$50 per vial, influenced by increased competition and manufacturing efficiencies.
- Revenue potential remains high, with global sales exceeding $2.5 billion annually, potentially nearing $3 billion by 2028.
- Competitive landscape emphasizes cost management and strategic positioning for market share expansion.
FAQs
Q1: What factors primarily influence the future price of paclitaxel?
Market competition, manufacturing costs, regulatory environment, and supply chain stability.
Q2: How does the entry of biosimilars affect paclitaxel prices?
Though biosimilars target biologics, generic small-molecule versions like paclitaxel face similar price pressures to maintain market share.
Q3: Are there regional differences in prices for NDC 00093-7164?
Yes. The U.S. generally exhibits higher prices due to regulatory and reimbursement frameworks, whereas emerging markets tend to have lower prices.
Q4: How might new indications or increased usage impact sales volume?
Additional approved indications and clinical adoption can significantly increase volume, boosting revenues even if prices decline.
Q5: What are the main challenges for manufacturers of NDC 00093-7164?
Maintaining cost competitiveness, navigating regulatory changes, managing supply chain disruptions, and countering increasing generic competition.
References
- GlobalData. (2023). Oncology Market Forecast to 2027.
- IQVIA. (2023). U.S. Prescription Drug Market Data.
- FDA. (2012). Approval and Patent Status of Paclitaxel.
- Statista. (2023). Global Oncology Drug Market Size and Forecast.
- Deloitte. (2022). Generic Drug Price Trends.
